Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf Gold

Showing results (11-20 of 700) with videos related to

Pageof 70
Sort By:
CNS Drugs|July 22, 2022
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future DevelopmentsSimon Faissner, Ralf Gold
Der Nervenarzt|March 3, 2021
[Disease-modifying treatment of secondary progressive multiple sclerosis]Olaf Hoffmann, Ralf Gold
Fortschritte Der Neurologie-Psychiatrie|November 30, 2019
[New therapeutic approaches in progressive multiple sclerosis]Simon Faissner, Ralf Gold
Cold Spring Harbor Perspectives in Medicine|March 4, 2018
Oral Therapies for Multiple SclerosisSimon Faissner, Ralf Gold
The Lancet. Neurology|March 12, 2014
Trial and error in clinical studies: lessons from ATAMSFred Lühder, Ralf Gold
Neurology|April 13, 2011
Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?Kerstin Hellwig, Ralf Gold
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Active immunotherapy may delay disability in progressive MSAiden Haghikia, Ralf Gold
MMW Fortschritte Der Medizin|September 7, 2013
[Multiple sclerosis: oral drugs]Aiden Haghikia, Ralf Gold
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2026
Beyond antibodies in GAD65 autoimmunity: Reframing pathogenesis through intrathecal B-T cell cross-talkSimon Faissner, Ralf Gold
The Lancet. Neurology|December 17, 2011
Multiple sclerosis: more pieces of the immunological puzzleRalf Gold, Xavier Montalban
Pageof 70

Showing results (11-20 of 700) with videos related to

Sort By:
Pageof 70
CNS Drugs|July 22, 2022
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future DevelopmentsSimon Faissner, Ralf Gold
Der Nervenarzt|March 3, 2021
[Disease-modifying treatment of secondary progressive multiple sclerosis]Olaf Hoffmann, Ralf Gold
Fortschritte Der Neurologie-Psychiatrie|November 30, 2019
[New therapeutic approaches in progressive multiple sclerosis]Simon Faissner, Ralf Gold
Cold Spring Harbor Perspectives in Medicine|March 4, 2018
Oral Therapies for Multiple SclerosisSimon Faissner, Ralf Gold
The Lancet. Neurology|March 12, 2014
Trial and error in clinical studies: lessons from ATAMSFred Lühder, Ralf Gold
Neurology|April 13, 2011
Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?Kerstin Hellwig, Ralf Gold
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Active immunotherapy may delay disability in progressive MSAiden Haghikia, Ralf Gold
MMW Fortschritte Der Medizin|September 7, 2013
[Multiple sclerosis: oral drugs]Aiden Haghikia, Ralf Gold
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2026
Beyond antibodies in GAD65 autoimmunity: Reframing pathogenesis through intrathecal B-T cell cross-talkSimon Faissner, Ralf Gold
The Lancet. Neurology|December 17, 2011
Multiple sclerosis: more pieces of the immunological puzzleRalf Gold, Xavier Montalban
Pageof 70